During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
News|Articles|September 1, 2007
Drug Watch: Agents in late-stage development for the treatment of allergic rhinitis and sinusitis/rhinosinusitis (September 2007) (PDF)
Agents in late-stage development for the treatment of allergic rhinitis and sinusitis/rhinosinusitis
Advertisement
Advertisement
Related to this article
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
Research findings scheduled to be presented at the CHEST meeting show broad positive cardiopulmonary effects from GLP-1s and an association with a reduced risk of acute respiratory failure.
Chad Hatfield, Pharm.D., of UC Davis Health, says 340B savings fund free clinics and mental health care that could shrink as the program’s future shifts.
Fewer than 1 in 5 eligible adults get lung cancer screening. Experts told MHE over email that health plans can help by easing cost, coverage and approval barriers.
Healthcare spending for employer-insured Americans rose by nearly 19%between 2019 and 2023, driven by higher prices, surging drug costs, and spending on hospital care, says the president and CEO of the Health Care Cost Institute.
All 46 people with HIV who started long-acting lenacapavir and cabotegravir at a University of California, San Francisco, clinic reached or kept viral suppression over a median of 100 weeks.
Luis Garza, M.D., Ph.D., a Johns Hopkins professor, says hidradenitis suppurativa is neither an infection nor a classic autoimmune disease but an auto-inflammatory condition.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Long-acting lenacapavir plus cabotegravir kept all 46 patients with HIV virally suppressed in recent trial
2
Chad Hatfield, Pharm.D., on the 340B uncertainty facing health systems| HSES 2026
3
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
4
On the relentless rise in healthcare spending, price vs. utilization, and what employers should do about it | A conversation with Katie Martin, M.P.A.
5